Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05712889 | Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer | PHASE1 | COMPLETED | 29 | — | — | Jan 24, 2023 | Oct 10, 2024 | Nov 15, 2024 | 6 | United States, Australia |
| Arm | Type | Description |
|---|---|---|
| Dose Escalation of VIP236 (Q3W) | EXPERIMENTAL | Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 of each 21-day cycle |
| Dose Escalation of VIP236 (Q2W) | EXPERIMENTAL | Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 and D15 of each 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| VIP236 (Q3W) | DRUG | VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle. |
| VIP236 (Q2W) | DRUG | VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle. |
Inclusion Criteria: * Adult patients aged \>/=18 years, able to provide informed consent and willing to comply with all study procedures. * Histologically confirmed advanced or metastatic solid tumors that are relapsed or refractory to standard of care. Subjects must have exhausted all available st...